The purpose of this study is to determine if administration of tranexamic acid (TXA), a
clotting agent, will decrease blood loss, the need for transfusion, and reduce the likelihood
of wound complications such as infection. Investigators will also see if the drug can
effectively decrease operative time and length of hospitalization.
Phase:
Phase 2
Details
Lead Sponsor:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)